

e-Therapeutics plc

("e-Therapeutics" or "the Company")

Director's shareholdings

e-Therapeutics plc (AIM: ETX), the network drug discovery and development company, announces that on 26 February 2010, the Self Invested Pension Plan ("SIPP") of John Cordiner acquired, in aggregate, 67,376 ordinary shares of 0.1p each in the Company ('Ordinary Shares') at an average price of 40.5p per share. Following this acquisition, Mr Cordiner and his SIPP have in aggregate an interest in 451,436 Ordinary Shares representing 0.7 % of the current issued share capital of the Company.

- Ends -

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

+44 (0) 191 233 1317

malcolm@etherapeutics.co.uk

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

+44 (0) 20 7050 6500

henry.fitzgerald-o'connor@canaccordadams.com

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

+44 (0) 20 7398 7700

simone.elviss@abchurch-group.com

Notes to Editors

About e-Therapeutics

e-Therapeutics plc pioneered network pharmacology in drug discovery. It has developed proprietary systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:

discovery of new drugs;
discovering novel uses for existing drugs; and
analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA and C.difficile, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products, two of which have completed Phase II trials successfully, and three of which have been out-licensed to pharmaceutical partners.

For further information on e-Therapeutics visit www.etherapeutics.co.uk.